Free Shipping to all UK customers for orders over £25.00
Free Shipping to all UK customers for orders over £25.00
Free Shipping to all UK customers for orders over £25.00
Product Categories
My Shopping Cart
You shopping cart is empty
You may browse our offerings to locate what you're searching for, then put it in your shopping cart.
In Silico Dreams
Usually dispatched within 3 - 5 business days.
£ 28.86
Learn how AI and data science are upending the worlds of biology and medicine In Silico Dreams: How Artificial Intelligence and Biotechnology Will Create the Medicines of the Future delivers an illuminating and fresh perspective on the convergence of two powerful technologies: AI and biotech. Accomplished genomics expert, executive, and author Brian Hilbush offers readers a brilliant exploration of the most current work of pioneering tech giants and biotechnology startups who have already started disrupting healthcare. The book provides an in-depth understanding of the sources of innovation that are driving the shift in the pharmaceutical industry away from serendipitous therapeutic discovery and toward engineered medicines and curative therapies. In this fascinating book, you'll discover: An overview of the rise of data science methods and the paradigm shift in biology that led to the in silico revolutionAn outline of the fundamental breakthroughs in AI and deep learning and their applications across medicineA compelling argument for the notion that AI and biotechnology tools will rapidly accelerate the development of therapeuticsA summary of innovative breakthroughs in biotechnology with a focus on gene editing and cell reprogramming technologies for therapeutic developmentA guide to the startup landscape in AI in medicine, revealing where investments are poised to shape the innovation base for the pharmaceutical industry Perfect for anyone with an interest in scientific topics and technology, In Silico Dreams also belongs on the bookshelves of decision-makers in a wide range of industries, including healthcare, technology, venture capital, and government.